NASDAQ:TYRA Tyra Biosciences Q4 2023 Earnings Report $10.39 -0.47 (-4.33%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$10.20 -0.19 (-1.82%) As of 07/18/2025 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Tyra Biosciences EPS ResultsActual EPS-$0.53Consensus EPS -$0.48Beat/MissMissed by -$0.05One Year Ago EPSN/ATyra Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ATyra Biosciences Announcement DetailsQuarterQ4 2023Date3/19/2024TimeN/AConference Call DateTuesday, March 19, 2024Conference Call Time8:00AM ETUpcoming EarningsTyra Biosciences' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Tyra Biosciences Earnings HeadlinesTyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025 - MorningstarJuly 9, 2025 | morningstar.comMTyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025July 8, 2025 | prnewswire.comBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket change. July 19 at 2:00 AM | Crypto 101 Media (Ad)Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302) - FinanzNachrichten.deJuly 2, 2025 | finanznachrichten.deTyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)June 30, 2025 | prnewswire.comTyra Biosciences to Participate at Upcoming Investor ConferencesMay 12, 2025 | prnewswire.comSee More Tyra Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tyra Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tyra Biosciences and other key companies, straight to your email. Email Address About Tyra BiosciencesTyra Biosciences (NASDAQ:TYRA) is a clinical‐stage biotechnology company focused on the discovery and development of precision medicines for metabolic and endocrine disorders. Leveraging proprietary covalent chemistry platforms, Tyra aims to target disease-relevant transcription factors and nuclear receptors that have historically been difficult to modulate with small molecules. The company’s pipeline includes several preclinical and early‐stage clinical candidates designed to address conditions such as nonalcoholic steatohepatitis (NASH) and other metabolic diseases, with a particular focus on improving liver function and systemic metabolic profiles. Founded in 2021 by leading life science investors and researchers, Tyra Biosciences is headquartered in San Diego, California—a hub for biotechnology innovation. The company was built on a foundation of collaborative research, combining deep expertise in medicinal chemistry with translational biology to accelerate the development of novel therapies. Tyra’s scientific team applies an integrated approach, from target identification and validation through medicinal chemistry optimization and in vivo proof-of-concept studies. Under the leadership of Chief Executive Officer Brian Lian, Tyra has assembled a management team with extensive experience in drug discovery, clinical development and regulatory strategy. The company continues to advance its most advanced programs toward clinical proof of concept while expanding its discovery efforts through ongoing partnerships and strategic collaborations. By focusing on innovative mechanisms of action and precision targeting, Tyra Biosciences seeks to address significant unmet needs in metabolic and endocrine diseases.Written by Jeffrey Neal JohnsonView Tyra Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings Report Upcoming Earnings NXP Semiconductors (7/21/2025)Verizon Communications (7/21/2025)Comcast (7/22/2025)Intuitive Surgical (7/22/2025)Texas Instruments (7/22/2025)America Movil (7/22/2025)Chubb (7/22/2025)Canadian National Railway (7/22/2025)Capital One Financial (7/22/2025)Danaher (7/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
